Tampalan pencegah hamil - Wikipedia Bahasa Melayu, ensiklopedia bebas

levonorgestrel / ethinyl estradiol
Kombinasi
Levonorgestrel	Progestogen
Ethinylestradiol	Estrogen
Data klinikal
Nama dagang	Twirla
Data lesen	AS DailyMed: Twirla;
Kategori; kehamilan	Ditunjuk kontra;
Kaedah; pemberian	Transdermal (tampalan)
Kod ATC	G03AB03 (WHO) ;
Status perundangan
Status perundangan	AS: Rx sahaja ;
Pengecam
ChemSpider	Tiada;

norelgestromin / ethinyl estradiol
Kombinasi
Norelgestromin	Progestogen
Ethinylestradiol	Estrogen
Data klinikal
Nama dagang	Ortho Evra, Xulane, Evra
AHFS/Drugs.com	Professional Drug Facts
MedlinePlus	a602006
Data lesen	EU EMA: by INN; AS DailyMed: Norelgestromin_and_ethinyl_estradiol;
Kategori; kehamilan	Ditunjuk kontra;
Kaedah; pemberian	Transdermal (tampalan)
Kod ATC	G03AA13 (WHO) ;
Status perundangan
Status perundangan	KA: ℞ sahaja ; UK: POM (Preskripsi sahaja) ; AS: Rx sahaja ; Rx sahaja;
Pengecam
Nombor CAS	53016-31-2 ; 57-63-6 ;
PubChem CID	91758695;
DrugBank	DB06713; DB00977;
ChemSpider	Tiada;
UNII	R0TAY3X631; 423D2T571U ;
KEGG	D10839 ;
Data kimia dan fizikal
Formula	C41H53NO4
Jisim molar	623.88 g·mol−1
Model 3D (JSmol)	Gambar interaktif;
	SMILES CCC12CCC3C(C1CCC2(C#C)O)CCC4=CC(=NO)CCC34.CC12CCC3C(C1CCC2(C#C)O)CCC4=C3C=CC(=C4)O;
	InChI InChI=1S/C21H29NO2.C20H24O2/c1-3-20-11-9-17-16-8-6-15(22-24)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2;1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h2,13,16-19,23-24H,3,5-12H2,1H3;1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/b22-15-;/t16-,17+,18+,19-,20-,21-;16-,17-,18+,19+,20+/m01/s1; Key:KBFRRZPPJPKFHQ-WKXKRCMPSA-N;

Tampalan pencegah hamil
Tampalan pencegah hamil
	Jenama Ortho Evra tampalan pencegah hamil
Latar belakang
Jenis	Hormon (estrogen + progestin tergabung)
Penggunaan pertama	2002
Kegagalan (tahun pertama)
Penggunaan sempurna	0.3%
Penggunaan tipikal	9%
Penggunaan
Peringatan pengguna	Penggunaan setiap minggu untuk 3 minggu
Ulasan klinikal	3-6 setiap bulan
Kelebihan dan kekurangan
Perlindungan STI	Tidak
Jisim	Tiada kesan terbukti
Period advantages	Dikawal, mungkin lebih ringan dan kurang sakit
Kebaikan	Berbanding pill oral, mungkin kurang terjejas oleh antibiotik
Risiko	Kadar DVT sama dengan pil tergabung oral

Tampalan pencegah hamil, juga dikenali sebagai "tampalan", ialah tampalan transdermal digunakan pada kulit yang mengeluarkan hormon estrogen dan progestogen tiruan untuk mencegah kehamilan. Ia telah menunjukkan menjadi berkesan sebagai pil pencegah hamil oral tergabung dengan penggunaan sempurna, dan tampalan boleh menjadi lebih berkesan dalam kegunaan biasa.^[3]^[4]

Rujukan

^ ^a ^b Trussell J (2011). "Contraceptive efficacy". Dalam Hatcher RA, Trussell J, Nelson AL, Cates Jr W, Kowal D, Policar MS (penyunting). Contraceptive technology (ed. 20th revised). New York: Ardent Media. m/s. 779–863. ISBN 978-1-59708-004-0. ISSN 0091-9721. OCLC 781956734. Table 26–1 = Table 3–2 Percentage of women experiencing an unintended pregnancy during the first year of typical use and the first year of perfect use of contraception, and the percentage continuing use at the end of the first year. United States.
^ "Evra transdermal patch - Summary of Product Characteristics (SmPC)". (emc). 26 June 2020. Dicapai pada 4 July 2020.
^ Trussell J (2007). "Contraceptive Efficacy". Dalam Hatcher RA, dll. (penyunting). Contraceptive Technology (ed. 19th rev.). New York: Ardent Media. ISBN 978-0-9664902-0-6.
^ Nanda K, Burke A (2011). "Contraceptive patch and vaginal contraceptive ring.". Dalam Hatcher RA, Nelson AL, Trussell J, Cwiak C, Cason P, Policar MS, Edelman A, Aiken AR, Marrazzo J, Kowal D (penyunting). Contraceptive Technology (ed. twentieth). Atlanta, Georgia: Ardent Media, Inc. m/s. 272. ISBN 978-1-59708-004-0.

Pautan luar

"Ethinyl Estradiol mixture with norelgestromin". Drug Information Portal. U.S. National Library of Medicine.
Feminist Women's Health Center
Planned Parenthood: The Patch

Templat:Birth control methods Templat:Hormonal contraceptives

[Trussell_2011-1] Trussell J (2011). "Contraceptive efficacy". Dalam Hatcher RA, Trussell J, Nelson AL, Cates Jr W, Kowal D, Policar MS (penyunting). Contraceptive technology (ed. 20th revised). New York: Ardent Media. m/s. 779–863. ISBN 978-1-59708-004-0. ISSN 0091-9721. OCLC 781956734. Table 26–1 = Table 3–2 Percentage of women experiencing an unintended pregnancy during the first year of typical use and the first year of perfect use of contraception, and the percentage continuing use at the end of the first year. United States.

[2] "Evra transdermal patch - Summary of Product Characteristics (SmPC)". (emc). 26 June 2020. Dicapai pada 4 July 2020.

[CT-3] Trussell J (2007). "Contraceptive Efficacy". Dalam Hatcher RA, dll. (penyunting). Contraceptive Technology (ed. 19th rev.). New York: Ardent Media. ISBN 978-0-9664902-0-6.

[4] Nanda K, Burke A (2011). "Contraceptive patch and vaginal contraceptive ring.". Dalam Hatcher RA, Nelson AL, Trussell J, Cwiak C, Cason P, Policar MS, Edelman A, Aiken AR, Marrazzo J, Kowal D (penyunting). Contraceptive Technology (ed. twentieth). Atlanta, Georgia: Ardent Media, Inc. m/s. 272. ISBN 978-1-59708-004-0.

[1]

[2]

[3]

[4]